About AML17
What is the purpose of the study?
Excerpt from Patient Information Sheet 1:
Everyone with a new diagnosis of acute myeloid leukaemia or AML
needs to have strong treatment with chemotherapy to try to get rid
of the leukaemia cells. There are different combinations of
chemotherapy drugs that can be used in treating AML. In this
study, we are testing if adding a new chemotherapy drug in the first
treatment you get will increase the number of people who will get
rid of their leukaemia cells. We call this remission or
complete remission (CR for short). This study will allow us to
compare the best treatments against each other so that we can always
make sure that we are using the best and improving this when we can.
When people get remission in AML, there is still a risk the
leukaemia can come back. To try to prevent this, we give more
courses of chemotherapy to kill off any leukaemia cells that got
missed in the first treatment. This is called consolidation
treatment. In consolidation, we want to test if some new drugs
that have been developed recently can improve our current best
treatments. Some of these are not chemotherapy themselves, but
are designed to attack specific targets in different people’s
leukaemia. At the moment, we don’t know if your leukaemia has
these targets, but we will find out while you are having your first
treatment.